Meghan Johnston is a laboratory scientist.

Huntington’s disease gene therapy: FDA reversal delays AMT-130

Meds
March 17, 2026

At the end of September 2025, a gene therapy company released results from a clinical trial showing that a breakthrough procedure reduced the progression of Huntington’s symptoms by 75 percent over three years. Researchers collected data from 12 participants who received the therapy and compared the data with two types of control groups.

The company’s drug, AMT-130, shows unprecedented outcomes, so why is the FDA slowing …

Read more…

Huntington’s disease gene therapy: FDA reversal delays AMT-130

Repeating history: the ethics of the new Guinea-Bissau hepatitis B study

Policy
March 13, 2026

In the late 1990s, a U.S.-funded study randomized HIV-positive pregnant women in Bangkok, Thailand, to either a placebo group or a group treated with a short course of AZT. At the time, AZT was the standard of care in the U.S., and researchers knew the medication protocol worked at reducing mother-to-child HIV transmission by nearly 70 percent. The study looked at whether a shortened protocol could meaningfully reduce …

Read more…

Repeating history: the ethics of the new Guinea-Bissau hepatitis B study